Overlooked P3 peptide may be reshaping the amyloid story in Alzheimer’s disease
For decades, Alzheimer’s disease research has revolved around amyloid beta, the peptide that clumps into plaques and has anchored a vast drug-development effort. Yet a new commentary in ChemBioChem argues that the field may have left out a closely related molecule with meaningful biologic activity of its own: P3, a shorter peptide generated through a different processing pathway of amyloid precursor protein.
Jevgenij Raskatov of the University of California, Santa Cruz, lays out a case that P3 is not a benign byproduct quietly drifting through the brain. In laboratory studies from his group over the past five years, P3 formed microscopic aggregates and threadlike fibrils, and it did so faster than amyloid beta. The peptide also showed evidence of neuronal toxicity, although the reported toxicity appeared lower than that of amyloid beta.
The implications are hard to ignore. If a peptide once assumed to be biologically irrelevant can seed aggregates and harm neurons, then decades of research centered almost entirely on amyloid beta may have been working with an incomplete map of the disease.
Why a smaller peptide could matter in a disease defined by protein misfolding
Amyloid beta originates when the amyloid precursor protein is cut first by β-secretase and then by γ-secretase. P3 comes from a different route: α-secretase acts first, followed by γ-secretase. For years, that alternate product was considered soluble, non-amyloidogenic, and unlikely to matter clinically. Raskatov argues that those assumptions were never adequately tested before they hardened into conventional wisdom.
The biology here is straightforward but consequential. In neurodegenerative disease, small shifts in peptide processing can alter whether proteins remain dispersed or begin to self-associate into toxic assemblies. Once aggregation starts, oligomers and fibrils can disrupt synapses, stress neurons, and amplify downstream injury. P3 appears capable of entering that same biochemical territory, even if it is a smaller molecule than amyloid beta.
Raskatov has proposed renaming P3 as “Amyloid α,” or Aα, to distinguish it from amyloid beta and to acknowledge its aggregation behavior. The terminology is less important than the underlying point: a peptide long treated as harmless may participate in the same disease chemistry that has dominated Alzheimer’s research for decades.
One sentence captures the disruption: P3 can aggregate faster than amyloid beta.
That finding is not just a laboratory curiosity. If P3 is present in the brain and interacts with amyloid beta, it could influence how much amyloid accumulates, how quickly it assembles, and how toxic the combined material becomes. The commentary says evidence suggests precisely that possibility, though the clinical significance still needs to be established in patients.
A broader target could help explain why amyloid-focused therapies have disappointed
The clinical backdrop matters. Alzheimer’s remains the most widespread neurodegenerative disease, affecting approximately 35 million people worldwide and generating annual costs exceeding $800 billion. The number of people living with the condition is expected to double by 2050. Against that burden, more than 400 clinical trials have investigated Alzheimer’s therapies, with most centered on amyloid beta. Many failed outright; others produced only modest benefit. Some amyloid-targeting therapies also carried serious risks, including brain hemorrhages and strokes.
Those disappointments have fueled debate over whether amyloid beta alone can explain the disease. Existing medications, including cholinesterase inhibitors and NMDA receptor antagonists, can ease symptoms temporarily, but they do not halt progression. More recent antibody therapies such as Lecanemab and Donanemab reduce amyloid burden, yet the room for improvement remains limited by the central problem that has shadowed the field for years: lowering a target does not necessarily reverse a complex neurodegenerative process already underway.
P3 may help explain part of that gap. If the peptide participates in aggregate formation on its own, and if it interacts with amyloid beta in ways that alter toxicity, then the disease process may involve more than a single protein species. In that scenario, a therapy aimed only at amyloid beta could reduce one pathological pathway while leaving another intact.
Raskatov says his laboratory’s findings have been independently confirmed and expanded by researchers in the United Kingdom, and additional groups are beginning to examine the relationship between P3 and amyloid beta. The open question is not whether amyloid biology matters. It does. The question is whether the field has been too narrow in deciding which amyloid-related molecules deserve attention.
The next task is not just confirmation, but patient-level relevance
The commentary also describes a troubling citation pattern: at least four papers in peer-reviewed journals reportedly cited the group’s work as evidence that P3 was harmless and incapable of forming amyloid deposits, even though the experiments demonstrated the opposite. In a field where mechanistic assumptions can shape funding priorities, trial design, and biomarker development, such misreadings can have real consequences.
Raskatov’s conclusion is direct: progress has been slow, and the current state of Alzheimer’s therapy leaves much to be desired. That is not rhetorical excess. It is a fair summary of a field that has spent years chasing one dominant protein while other amyloid-like species may have been sitting in plain view.
For now, the strongest claim is biological rather than clinical. P3 can aggregate, may injure neurons, and could interact with amyloid beta in ways that change disease behavior. What remains unproven is whether those laboratory effects translate into measurable differences in human Alzheimer’s progression, imaging findings, or treatment response.
The field now has to decide whether P3 is a side character or part of the main plot. The answer will determine whether future Alzheimer’s therapies continue to focus on amyloid beta alone or expand to include a wider set of aggregation-prone peptides that may help drive neuronal injury.